North American Scientific Announces FDA Clearance of its ClearPath HDR Breast Brachytherapy System
14th Nov 2006, 17:59 GMT
North American Scientific announced that the Company has received 510 clearance from the US FDA to market the high-dose rate radiation treatment design of ClearPath, its breast brachytherapy product introduced this month at the 48th Annual Meeting of the American Society of Therapeutic Radiology and Oncology.
North American Scientific Announces FDA Clearance of its ClearPath HDR Breast Brachytherapy System related news:
- North American gets FDA approval for breast cancer treatment — Latest news from Los Angeles Business from bizjournals
- North American Gets Cancer Treatment OK — FDA News News from StratCenter.com
- ReGen Biologics Announces Results of FDA Appeal — Government/ Industry Regulation News from StratCenter.com
- Radiation Heart Dose From MammoSite Compared To IMRT For Left-Sided Breast Cancers — Health News from Medical News Today
- Two PITT researchers make Scientific American 50 of Leaders in Science and Technology — EurekAlert! - Chemistry, Physics and Materials Sciences
- Two Pitt researchers make 'Scientific American 50' of leaders in science and technology — EurekAlert! - Chemistry, Physics and Materials Sciences
- FDA should return to 'science-based' agency — News-Medical News Feed
- Scientific American names UCSB professor, alumna to list of Top 50 in Technological Leadership — EurekAlert! - Technology, Engineering and Computer Science
- - Webcast Alert: Isis Pharmaceuticals Announces Its Analyst/Investor Webcast Presentation — Partnerships/ Joint Ventures News from StratCenter.com
- North American Palladium Ltd.: North American Palladium Reports Third Quarter of Improved Financial Results — Market Wire - Manufacturing and Production
Latest news from FDA News News from StratCenter.com:
- North American Gets Cancer Treatment OK
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ.
- ACT-AD Coalition Calls FDA's New Focus on Neurological Diseases a Positive 1st Step
- Ivax Diagnostics Delays Filing 3Q Report
- New Corporate Members and Leaders for C-Path's Predictive Safety Testing Consortium Announced
- Diagnosoft Receives FDA Approval for Cardiac MRI Quantitative Regional Function Software Based on the HARP Technology
- PAREXEL Consulting Expands Risk Mgmt Expertise, Appoints Former FDA Consumer Safety Officer Raymond T Oji as Senior Consultant
- Trubion Pharmaceuticals to Present at the Lazard Life Sciences Conference
- Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting
- FermaVir's Founder and Board Member Professor Chris McGuigan receives the Royal Society of Chemistry's Award for Medicinal Chemistry